Following a full submission
AWMSG advice |
||
| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED AUGUST 2007 AND UPDATED AUGUST 2010. Refer to TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | adalimumab (Humira®) | |
| Formulation | 40 mg solution for injection | |
| Reference number | 6 | |
| Indication | Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate |
|
| Company | AbbVie Ltd | |
| BNF chapter | Musculoskeletal & joint diseases | |
| Submission type | Full | |
| Status | Superseded | |
| AWMSG meeting date | 07/06/2006 | |
| Ratification by Welsh Government | 28/07/2006 | |
| Date of issue | 02/08/2006 | |
| NICE guidance | TA199: etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis |
|